Dynavax to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) will announce its second quarter 2020 financial results on August 6, 2020, after market close. A conference call and audio webcast will follow at 4:30 p.m. ET. The company, known for developing novel vaccines, launched HEPLISAV-B® in February 2018, and is advancing CpG 1018 as a vaccine adjuvant with partnerships focused on vaccines for COVID-19, pertussis, and universal influenza. Access to the webcast will be available on their website, with a replay for 30 days post-event.

Positive

• Dynavax launched HEPLISAV-B® in February 2018, contributing to market presence.
• Current collaborations include vaccine adjuvants for COVID-19 and other diseases, potentially enhancing future revenue.

Negative

• None.

EMERYVILLE, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2020 financial results on Thursday, August 6, 2020, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, August 6, 2020 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the “Events & Presentations” page on the “Investors” section of the Company’s website at www.dynavax.com.  Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 8187870.  A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.  Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.   Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

FAQ

When will Dynavax report its second quarter 2020 financial results?

Dynavax will report its second quarter 2020 financial results on August 6, 2020, after market close.

What time is the Dynavax conference call on August 6, 2020?

The Dynavax conference call is scheduled for 4:30 p.m. ET on August 6, 2020.

How can I access the Dynavax earnings call?

The Dynavax earnings call can be accessed via the 'Events & Presentations' section on their website or by dialing the provided conference call numbers.

What is HEPLISAV-B®?

HEPLISAV-B® is a Hepatitis B vaccine launched by Dynavax in February 2018, approved for preventing infection from all known subtypes of the hepatitis B virus.

What collaborations is Dynavax currently involved in?

Dynavax is currently focused on collaborations for adjuvanted vaccines targeting COVID-19, pertussis, and universal influenza.